Literature DB >> 11701743

Increased expression of cyclooxygenase-2 in malignant pheochromocytomas.

K Salmenkivi1, C Haglund, A Ristimäki, J Arola, P Heikkilä.   

Abstract

Pheochromocytomas are rare tumors of the adrenal medulla or the paraganglion system. There are no histological or chemical markers available that define the malignant behavior of these tumors; so far only the discovery of metastases reveals malignancy. Cyclooxygenase (Cox) is the key enzyme in conversion of arachidonic acid to PGs, and two isoforms, Cox-1 and Cox-2, have been identified. Cox-2 has been associated with carcinogenesis, and it is overexpressed in many human malignancies. We have now investigated the expression of Cox-2 in normal adrenal gland, in 92 primary pheochromocytomas and in six metastases using immunohistochemistry and Northern blot and Western blot analyses. Cox-2 protein was expressed in the adrenal cortex, whereas the medulla was negative as detected by immunohistochemistry. Interestingly, all malignant pheochromocytomas (n = 8), regardless of the primary location of the tumor, showed moderate or strong Cox-2 immunoreactivity, whereas 75% of the benign adrenal tumors (n = 36) showed no or only weak immunopositivity. The staining was negative or weak in 79% of the adrenal tumors that showed histologically suspicious features (n = 24), but had not metastasized. Most of the pheochromocytoma samples studied also expressed low levels of Cox-2 mRNA. Our data show that normal adrenal medulla does not express Cox-2 immunohistochemically. However, strong Cox-2 protein expression was found in malignant pheochromocytomas, whereas most benign tumors expressed Cox-2 only weakly. To our knowledge, this is the first report on Cox-2 expression in pheochromocytomas and enhanced expression in malignant pheochromocytomas. These findings suggest that negative or weak Cox-2 expression in pheochromocytomas favors benign diagnosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11701743     DOI: 10.1210/jcem.86.11.8052

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  17 in total

Review 1.  Cyclooxygenase-2 and thromboxane synthase in non-endocrine and endocrine tumors: a review.

Authors:  Onder Onguru; Mary B Casey; Sabine Kajita; Nobuki Nakamura; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

2.  A logistic regression model for predicting malignant pheochromocytomas.

Authors:  Baohua Gao; Yanxia Sun; Zhongguo Liu; Fanwei Meng; Benkang Shi; Yuqiang Liu; Zhishun Xu
Journal:  J Cancer Res Clin Oncol       Date:  2007-11-13       Impact factor: 4.553

3.  MRTFB suppresses colorectal cancer development through regulating SPDL1 and MCAM.

Authors:  Takahiro Kodama; Teresa A Marian; Hubert Lee; Michiko Kodama; Jian Li; Michael S Parmacek; Nancy A Jenkins; Neal G Copeland; Zhubo Wei
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-05       Impact factor: 11.205

4.  Celecoxib reduces glucocorticoids in vitro and in a mouse model with adrenocortical hyperplasia.

Authors:  Sisi Liu; Emmanouil Saloustros; Annabel Berthon; Matthew F Starost; Isabelle Sahut-Barnola; Paraskevi Salpea; Eva Szarek; Fabio R Faucz; Antoine Martinez; Constantine A Stratakis
Journal:  Endocr Relat Cancer       Date:  2015-10-05       Impact factor: 5.678

Review 5.  Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.

Authors:  Oliver Gimm; Catherine DeMicco; Aurel Perren; Francesco Giammarile; Martin K Walz; Laurent Brunaud
Journal:  Langenbecks Arch Surg       Date:  2011-11-29       Impact factor: 3.445

6.  Heparanase-1 and Cyclooxygenase-2: prognostic indicators of malignancy in pheochromocytomas.

Authors:  Yu Zhu; Hong-chao He; Fei Yuan; Jun Zhang; Wen-bin Rui; Ju-ping Zhao; Zhou-jun Shen; Guang Ning
Journal:  Endocrine       Date:  2010-06-18       Impact factor: 3.633

7.  Does administration of non-steroidal anti-inflammatory drug determine morphological changes in adrenal cortex: ultrastructural studies.

Authors:  Włodzimierz Matysiak; Barbara Jodłowska-Jedrych
Journal:  Protoplasma       Date:  2010-08-19       Impact factor: 3.356

8.  Tumor necrosis factor (TNF)-alpha persistently activates nuclear factor-kappaB signaling through the type 2 TNF receptor in chromaffin cells: implications for long-term regulation of neuropeptide gene expression in inflammation.

Authors:  Djida Ait-Ali; Valérie Turquier; Yannick Tanguy; Erwan Thouënnon; Hafida Ghzili; Lourdes Mounien; Céline Derambure; Sylvie Jégou; Jean-Philippe Salier; Hubert Vaudry; Lee E Eiden; Youssef Anouar
Journal:  Endocrinology       Date:  2008-02-21       Impact factor: 4.736

Review 9.  Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas.

Authors:  Hilde Dannenberg; Paul Komminoth; Winand N M Dinjens; Ernst Jan M Speel; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

10.  Global tumor RNA expression in early establishment of experimental tumor growth and related angiogenesis following COX-inhibition evaluated by microarray analysis.

Authors:  Hans Axelsson; Christina Lönnroth; Marianne Andersson; Wenhua Wang; Kent Lundholm
Journal:  Cancer Inform       Date:  2007-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.